Shenghui Tang

Medicine

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 100%percentile

0Author DataRank

Indexed papers

0in pilot corpus

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Papers

Driven by 23 papers. Top paper: “FDA Approval Summary: Mirvetuximab Soravtansine-Gynx for FRα-Positive, Platinum-Resistant Ovarian Cancer”.

FDA Approval Summary: Mirvetuximab Soravtansine-Gynx for FRα-Positive, Platinum-Resistant Ovarian Cancer

Clinical Cancer Research(2023)10.1158/1078-0432.ccr-23-0991

N/A

2.9DataRank · unranked

108 citations

Mirat Shah, Gwynn Ison, Haley Gittleman, Mallorie H. Fiero, Ankit Shah +20 more

US Food and Drug Administration Approval Summary: Capivasertib With Fulvestrant for Hormone Receptor–Positive, Human Epidermal Growth Factor Receptor 2–Negative Locally Advanced or Metastatic Breast Cancer With PIK3CA / AKT1 / PTEN Alterations

Journal of Clinical Oncology(2024)10.1200/jco.24.00427

N/A

0.978DataRank · unranked

41 citations

James Buturla, Christy Osgood, Xin Gao, Wei Chen, Tiffany K. Ricks +14 more

FDA Approval Summary: Fam-Trastuzumab Deruxtecan-Nxki for the Treatment of Unresectable or Metastatic HER2-Positive Breast Cancer

Clinical Cancer Research(2021)10.1158/1078-0432.ccr-20-4557

N/A

0DataRank · unranked

164 citations

Christy Osgood, Harpreet Singh, Haw-Jyh Chiu, Tiffany K. Ricks, Edwin C.Y. Chow +14 more

U.S. FDA Drug Approvals for Breast Cancer: A Decade in Review

Clinical Cancer Research(2021)10.1158/1078-0432.ccr-21-2600

N/A

0DataRank · unranked

72 citations

Preeti Narayan, Christy Osgood, Suparna Wedam, Tatiana M. Prowell, Jennifer Gao +17 more

FDA Approval Summary: Tivozanib for Relapsed or Refractory Renal Cell Carcinoma

Clinical Cancer Research(2021)10.1158/1078-0432.ccr-21-2334

N/A

0DataRank · unranked

45 citations

Chana Weinstock, Lijun Zhang, Mallorie H. Fiero, Miao Zhao, Eias Zahalka +14 more

FDA Approval Summary: Margetuximab plus Chemotherapy for Advanced or Metastatic HER2-Positive Breast Cancer

Clinical Cancer Research(2021)10.1158/1078-0432.ccr-21-3247

N/A

0DataRank · unranked

39 citations

Christy Osgood, Anup Amatya, Mallorie H. Fiero, C.J. George Chang, Tiffany K. Ricks +32 more

Subgroup Analyses in Oncology Trials: Regulatory Considerations and Case Examples

Clinical Cancer Research(2021)10.1158/1078-0432.ccr-20-4912

N/A

0DataRank · unranked

29 citations

Mallorie H. Fiero, Erik Bloomquist, A. K. Sinha, Steven J. Lemery, Harpreet Singh +13 more

U.S. FDA Drug Approvals for Gynecological Malignancies: A Decade in Review

Clinical Cancer Research(2021)10.1158/1078-0432.ccr-21-2599

N/A

0DataRank · unranked

23 citations

Preeti Narayan, Gwynn Ison, Tara Berman, Daniel L. Suzman, Suparna Wedam +18 more

FDA Approval Summary: Lutetium Lu 177 Vipivotide Tetraxetan for Patients with Metastatic Castration-Resistant Prostate Cancer

Clinical Cancer Research(2022)10.1158/1078-0432.ccr-22-2875

N/A

0DataRank · unranked

231 citations

Sundeep Agrawal, Haley Gittleman, Mallorie H. Fiero, Sriram Subramaniam, Christy S. John +14 more

FDA Approval Summary: Belzutifan for von Hippel-Lindau Disease–Associated Tumors

Clinical Cancer Research(2022)10.1158/1078-0432.ccr-22-1054

N/A

0DataRank · unranked

175 citations

Michael H. Brave, Chana Weinstock, Gautam U. Mehta, Diana Bradford, Haley Gittleman +17 more

FDA Approval Summary: Ripretinib for Advanced Gastrointestinal Stromal Tumor

Clinical Cancer Research(2022)10.1158/1078-0432.ccr-22-2400

N/A

0DataRank · unranked

12 citations

Leslie Doros, Margaret Thompson, Sirisha L. Mushti, Rosane Charlab, Elizabeth I. Spehalski +8 more

FDA Approval Summary: Ribociclib Indicated for Male Patients with Hormone Receptor–Positive, HER2-Negative Advanced or Metastatic Breast Cancer

Clinical Cancer Research(2023)10.1158/1078-0432.ccr-23-1133

N/A

0DataRank · unranked

9 citations

Christy Osgood, Zhou Feng, Erik Bloomquist, Shenghui Tang, C.J. George Chang +8 more

FDA Approval Summary: Enfortumab Vedotin plus Pembrolizumab for Locally Advanced or Metastatic Urothelial Carcinoma

Clinical Cancer Research(2024)10.1158/1078-0432.ccr-24-1393

N/A

0DataRank · unranked

32 citations

William F. Maguire, Chana Weinstock, Hui Zhang, Xin Gao, Fang Li +14 more

FDA Approval Summary: Fruquintinib for the Treatment of Refractory Metastatic Colorectal Cancer

Clinical Cancer Research(2024)10.1158/1078-0432.ccr-24-0281

N/A

0DataRank · unranked

25 citations

Sandra J. Casak, Sirisha L. Mushti, Joyce Cheng, Brian J. Christmas, Matthew D. Thompson +16 more

FDA Approval Summary: Durvalumab and Pembrolizumab, Immune Checkpoint Inhibitors for the Treatment of Biliary Tract Cancer

Clinical Cancer Research(2024)10.1158/1078-0432.ccr-24-0517

N/A

0DataRank · unranked

23 citations

Vaibhav Kumar, Chi Song, Mengdie Yuan, Anup Amatya, Joyce Cheng +9 more

FDA Approval Summary: Enfortumab Vedotin plus Pembrolizumab for Cisplatin-Ineligible Locally Advanced or Metastatic Urothelial Carcinoma

Clinical Cancer Research(2024)10.1158/1078-0432.ccr-23-3738

N/A

0DataRank · unranked

18 citations

Daniel Lee, Chana Weinstock, Xin Gao, Catharine C. Bulik, Sundeep Agrawal +9 more

FDA Approval Summary: Tovorafenib for Relapsed or Refractory BRAF-Altered Pediatric Low-Grade Glioma

Clinical Cancer Research(2025)10.1158/1078-0432.ccr-24-3439

N/A

0DataRank · unranked

21 citations

Diana Bradford, Somak Chatterjee, Xiaoxue Li, Stephanie Aungst, Amy M. Skinner +22 more

FDA Approval Summary: Datopotamab Deruxtecan-dlnk for Treatment of Patients with Unresectable or Metastatic, HR-Positive, HER2-Negative Breast Cancer

Clinical Cancer Research(2025)10.1158/1078-0432.ccr-25-1388

N/A

0DataRank · unranked

13 citations

Mirat Shah, Lijun Zhang, Joyce Cheng, Mary Kate Bonner, Melissa A. Pegues +22 more

FDA Approval Summary: Vorasidenib for IDH -Mutant Grade 2 Astrocytoma or Oligodendroglioma Following Surgery

Clinical Cancer Research(2025)10.1158/1078-0432.ccr-25-1333

N/A

0DataRank · unranked

12 citations

Amy Barone, Stephanie Aungst, Claudia P. Miller, Suryatheja Ananthula, Youwei Bi +20 more

FDA Approval Summary: Nogapendekin Alfa Inbakicept-pmln with BCG for BCG-Unresponsive Carcinoma In Situ

Clinical Cancer Research(2025)10.1158/1078-0432.ccr-25-1231

N/A

0DataRank · unranked

9 citations

Elaine Chang, Hee‐Koung Joeng, Mallorie H. Fiero, Lingshan Wang, Salaheldin S. Hamed +15 more

FDA Approval Summary: Alpelisib Plus Fulvestrant for Patients with HR-positive, HER2-negative, PIK3CA-mutated, Advanced or Metastatic Breast Cancer

Clinical Cancer Research(2020)10.1158/1078-0432.ccr-20-3652

N/A

0DataRank · unranked

169 citations

Tatiana M. Prowell, Jennifer Gao, Laura L. Fernandes, Emily Li, Xiling Jiang +29 more

FDA Approval Summary: Niraparib plus Abiraterone Acetate Fixed-Dose Combination for BRCA -Mutated Metastatic Castration-Resistant Prostate Cancer

Clinical Cancer Research(2025)10.1158/1078-0432.ccr-25-0883

N/A

0DataRank · unranked

0 citations

Dow-Chung Chi, Sundeep Agrawal, Hee‐Koung Joeng, Sarah Kim-McOlash, Wimolnut Manheng +17 more

FDA Approval Summary: Lurbinectedin for the Treatment of Metastatic Small Cell Lung Cancer

Clinical Cancer Research(2020)10.1158/1078-0432.ccr-20-3901

N/A

0DataRank · unranked

101 citations

Adnan A. Jaigirdar, Flora Mulkey, Joyce Cheng, Salaheldin S. Hamed, Yangbing Li +16 more